. Although infection, trauma, and angiogenic factor upregulation have been proposed, the etiology of PG remains unknown (Ahuja et al., 2013; Giblin et al., 2007) .
Prior to the start of our investigation, the Yale Human Investigation Committee approved the study protocol and all subjects provided written, informed consent. To identify somatic mutations driving the formation of lobular vascular tumors, we utilized pairwise wholeexome sequencing (WES) of blood and affected tissue in two patients. The first (VASC100) was a 5 year-old boy with a 1cm compressible, pulsatile tumor on the left helix which had enlarged and reddened over four months (Figure 1a) . Histologically, it contained lobules of benign-appearing endothelial cells (Figure 1b, c) . The second (VASC101) was a healthy male infant who had a pedunculated vascular nodule on the medial left lower eyelid at birth undetected by prenatal ultrasound (Figure 1d ). Despite prednisone and propranolol treatment, the lesion grew rapidly. Histopathology showed lobules of small caliber capillaries, extensive necrosis, and intervening foci with dilated vessels, some with valves ( Figure 1e , f).
Following pairwise WES, somatic mutations were identified (Supplementary Materials and Methods online). A heterozygous KRAS c.35G>A, p.G12D mutation and a heterozygous NRAS c.181C>A, p.Q61K mutation were found in VASC100 and VASC101 tumors, respectively (Table 1 and Supplementary Tables S1 and S2 GLMN, VEGRF3, FOXC2, SOX18, ACVRLK1, MADH4, and ENG (Ye et al., 2011) . No evidence of secondary somatic variants or regions of loss of heterozygosity (LOH) was found, suggesting both cases are true somatic RASopathies (Supplementary Figure S3 online ). Total number of somatic mutations were comparable between blood and tissue, demonstrating no increased mutation burden in tumor.
Recognizing that PGs share the lobular architecture found in VASC100 and 101 tumors, we screened paired lesional and normal tissue of 40 archival PG samples from adolescent patients (age <18) for RAS mutation via Sanger sequencing. This age range was selected as our exome cases were young children, and PGs commonly affect this age group. Four (4/40, 10%, VASC102, VASC103, VASC104, and VASC105) had somatic RAS mutations (Table  1 ) and all showed lobules of small caliber vessels . Both VASC102 and VASC104 PGs had a heterozygous c.182A>G, p.Q61R mutation in HRAS, while VASC103 and VASC105 PGs had a heterozygous c.145G>A, p.E49K and a heterozygous c.37G>A, p.G13S mutation in HRAS, respectively (Table 1 Previously identified somatic mutations in vascular tumors or malformations have involved key angiogenic players such as TEK, a tyrosine kinase involved in vascular remodeling, and the VEGFR receptor (Ye et al., 2011) . While somatic mutation in RAS has not been reported in human PG or vascular tumors, RAS signaling is associated with angiogenesis and vascular proliferation (Kranenburg et al., 2004) . Tumor cells expressing activated KRAS show increased VEGF synthesis, via stabilization of VEGF mRNA or increased phosphorylation of HIF-1a, a transcription factor for VEGF (Kranenburg et al., 2004) . Transgenic KRAS G12D mice spontaneously develop multiple vascular tumors, with endothelial cells demonstrating a RAS-dependent increase in VEGF and Flk-1 mRNA (Fisher et al., 2001) . RAS mutant endothelial cells acquire an angiogenic phenotype, including membrane ruffling, branching morphogenesis, increased DNA synthesis, and cell migration (Meadows et al., 2004) . Constitutively active HRAS G12V fibroblasts and KRAS mutant intestinal epithelial cells demonstrate enhanced expression of COX-2, which increases synthesis of proangiogenic cytokines and prostaglandins, further stimulating these factors via positive feedback (Kranenburg et al., 2004) . For archival PG lesions without RAS mutations, it is possible that they harbor mutations in distinct regulators of angiogenesis, or other genes in the RAS pathway.
Germline RASopathies provide further evidence for Ras-MAPK activity in vascular tumorigenesis. PG occurs in Costello syndrome due to HRAS mutations (Morice- Picard et al., 2013) , and a congenital ulcerating hemangioma was reported in a case of cardio-faciocutaneous syndrome with a germline KRAS mutation (Tang et al., 2007) . Additionally, germline mutations in RASA1, a RAS p21 protein activator, cause capillary malformationarteriovenous malformation (CM-AVM), which features an increased number of dermal capillaries (Eerola et al., 2003) .
Our reported RAS mutations have been found in cancer, including codon 12, 13 and 61 mutations which are well-established hotspots for constitutive activation of Ras-MAPK signaling. The HRAS E49K variant in VASC103 is at a less commonly implicated site; to date, mutations at this position have only been reported in somatic NRAS and KRAS-driven neoplasms (Palomba et al., 2012; Reifenberger et al., 2004) .
Our identification of somatic RAS mutations in vascular tumors has clinical relevance. Current therapies against these lesions are limited to steroids and β-blockers, which achieve mixed results, often limited to tumor size reduction without resolution (Wine Lee et al., 2014) . Some infantile vascular tumors, like VASC101, are unresponsive to such interventions (Wine Lee et al., 2014) . These cases may harbor RAS mutations, and might respond to farnesyl transferase inhibitors (FTIs) or Raf/Mek/Erk inhibitors which block signaling upstream or downstream of RAS. The finding that RAS mutation drives vascular tumors provides potential opportunities to develop targeted therapies for current drugresistant lesions. Table 1 RAS mutation identified in six vascular tumors. 
